Actinium Pharmaceuticals IncNYSE American:ATNM
- LAST PRICE7.3700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.0000/ 5
- Ask / Lots8.0700/ 1
- Open / Previous Close0.0000 / 7.3700
- Day Range---
- 52 Week Range
- Volume11
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATNM |
|---|---|---|
| 09:32 ET | 4728 | 7.1999 |
| 09:38 ET | 1655 | 7.125 |
| 09:39 ET | 317 | 7.1224 |
| 09:41 ET | 4292 | 7.055 |
| 09:43 ET | 600 | 7.01 |
| 09:45 ET | 1100 | 7.045 |
| 09:48 ET | 6300 | 7.09 |
| 09:50 ET | 1529 | 7.095 |
| 09:52 ET | 500 | 7.095 |
| 09:54 ET | 100 | 7.095 |
| 09:57 ET | 2442 | 7.09 |
| 09:59 ET | 2010 | 7.09 |
| 10:01 ET | 1160 | 7.1 |
| 10:03 ET | 138 | 7.135 |
| 10:06 ET | 100 | 7.14 |
| 10:08 ET | 519 | 7.145 |
| 10:10 ET | 300 | 7.16 |
| 10:12 ET | 1401 | 7.13 |
| 10:14 ET | 200 | 7.125 |
| 10:15 ET | 300 | 7.09 |
| 10:17 ET | 324 | 7.093 |
| 10:19 ET | 1073 | 7.07 |
| 10:21 ET | 400 | 7.09 |
| 10:24 ET | 1630 | 7.11 |
| 10:26 ET | 100 | 7.11 |
| 10:28 ET | 100 | 7.115 |
| 10:30 ET | 232 | 7.115 |
| 10:32 ET | 200 | 7.09 |
| 10:33 ET | 400 | 7.09 |
| 10:35 ET | 2113 | 7.06 |
| 10:37 ET | 300 | 7.07 |
| 10:39 ET | 408 | 7.06 |
| 10:42 ET | 400 | 7.085 |
| 10:44 ET | 537 | 7.06 |
| 10:46 ET | 3007 | 7.055 |
| 10:48 ET | 2150 | 7.02 |
| 10:50 ET | 200 | 7 |
| 10:51 ET | 300 | 7 |
| 10:53 ET | 2292 | 7.07 |
| 10:55 ET | 800 | 7.135 |
| 11:00 ET | 450 | 7.165 |
| 11:02 ET | 200 | 7.19 |
| 11:04 ET | 245 | 7.165 |
| 11:06 ET | 100 | 7.14 |
| 11:08 ET | 100 | 7.19 |
| 11:11 ET | 1100 | 7.14 |
| 11:13 ET | 600 | 7.16 |
| 11:15 ET | 2137 | 7.19 |
| 11:18 ET | 100 | 7.24 |
| 11:22 ET | 167 | 7.26 |
| 11:26 ET | 300 | 7.265 |
| 11:27 ET | 100 | 7.29 |
| 11:31 ET | 200 | 7.24 |
| 11:33 ET | 100 | 7.28 |
| 11:36 ET | 200 | 7.29 |
| 11:38 ET | 2565 | 7.34 |
| 11:40 ET | 400 | 7.3 |
| 11:42 ET | 800 | 7.3 |
| 11:44 ET | 800 | 7.305 |
| 11:45 ET | 1800 | 7.3305 |
| 11:47 ET | 2054 | 7.39 |
| 11:49 ET | 200 | 7.395 |
| 11:51 ET | 100 | 7.42 |
| 11:54 ET | 100 | 7.42 |
| 11:56 ET | 100 | 7.42 |
| 12:00 ET | 856 | 7.38 |
| 12:02 ET | 100 | 7.34 |
| 12:07 ET | 200 | 7.36 |
| 12:09 ET | 100 | 7.38 |
| 12:12 ET | 100 | 7.38 |
| 12:14 ET | 700 | 7.34 |
| 12:20 ET | 500 | 7.315 |
| 12:36 ET | 400 | 7.3 |
| 12:39 ET | 100 | 7.33 |
| 12:43 ET | 1700 | 7.4 |
| 12:45 ET | 100 | 7.42 |
| 12:52 ET | 1300 | 7.425 |
| 12:56 ET | 100 | 7.42 |
| 12:57 ET | 600 | 7.38 |
| 01:01 ET | 100 | 7.38 |
| 01:06 ET | 250 | 7.39 |
| 01:10 ET | 2919 | 7.385 |
| 01:12 ET | 200 | 7.37 |
| 01:15 ET | 600 | 7.37 |
| 01:19 ET | 853 | 7.35 |
| 01:24 ET | 300 | 7.36 |
| 01:26 ET | 100 | 7.35 |
| 01:30 ET | 400 | 7.35 |
| 01:32 ET | 100 | 7.39 |
| 01:33 ET | 100 | 7.35 |
| 01:37 ET | 200 | 7.37 |
| 01:39 ET | 1175 | 7.34 |
| 01:42 ET | 100 | 7.33 |
| 01:46 ET | 400 | 7.32 |
| 01:50 ET | 100 | 7.29 |
| 01:53 ET | 200 | 7.24 |
| 01:55 ET | 584 | 7.29 |
| 02:02 ET | 200 | 7.27 |
| 02:04 ET | 300 | 7.28 |
| 02:08 ET | 200 | 7.27 |
| 02:09 ET | 100 | 7.31 |
| 02:11 ET | 100 | 7.29 |
| 02:15 ET | 294 | 7.29 |
| 02:20 ET | 100 | 7.28 |
| 02:24 ET | 700 | 7.32 |
| 02:27 ET | 200 | 7.31 |
| 02:29 ET | 100 | 7.35 |
| 02:31 ET | 300 | 7.37 |
| 02:33 ET | 100 | 7.38 |
| 02:36 ET | 323 | 7.38 |
| 02:38 ET | 200 | 7.38 |
| 02:40 ET | 300 | 7.348 |
| 02:42 ET | 300 | 7.34 |
| 02:45 ET | 562 | 7.33 |
| 02:49 ET | 600 | 7.36 |
| 02:51 ET | 813 | 7.35 |
| 02:54 ET | 526 | 7.33 |
| 02:58 ET | 100 | 7.33 |
| 03:02 ET | 200 | 7.33 |
| 03:05 ET | 200 | 7.33 |
| 03:07 ET | 100 | 7.31 |
| 03:09 ET | 100 | 7.28 |
| 03:12 ET | 100 | 7.31 |
| 03:14 ET | 200 | 7.28 |
| 03:16 ET | 1089 | 7.29 |
| 03:18 ET | 100 | 7.32 |
| 03:20 ET | 300 | 7.31 |
| 03:21 ET | 100 | 7.31 |
| 03:23 ET | 500 | 7.31 |
| 03:27 ET | 620 | 7.32 |
| 03:30 ET | 1075 | 7.32 |
| 03:32 ET | 100 | 7.31 |
| 03:34 ET | 2634 | 7.3699 |
| 03:36 ET | 2662 | 7.3735 |
| 03:38 ET | 3349 | 7.42 |
| 03:39 ET | 818 | 7.42 |
| 03:41 ET | 1034 | 7.395 |
| 03:43 ET | 1400 | 7.39 |
| 03:45 ET | 403 | 7.41 |
| 03:48 ET | 613 | 7.4101 |
| 03:50 ET | 2026 | 7.36 |
| 03:52 ET | 614 | 7.365 |
| 03:54 ET | 500 | 7.4 |
| 03:56 ET | 3608 | 7.365 |
| 03:57 ET | 1501 | 7.34 |
| 03:59 ET | 2974 | 7.37 |
Jun 18, 2024
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions, from 8:46AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:46AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 17, 2024
DJ Actinium Pharmaceuticals Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 10:55AM ET on Monday Jun 17, 2024 by Dow Jones
10:55AM ET on Monday Jun 17, 2024 by Dow JonesAcute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase, from 9:45AM ET on Monday Jun 17, 2024 by Dow Jones
9:45AM ET on Monday Jun 17, 2024 by Dow JonesAcute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies, from 9:00AM ET on Monday Jun 17, 2024 by Dow Jones
9:00AM ET on Monday Jun 17, 2024 by Dow JonesBiopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML), from 8:46AM ET on Monday Jun 17, 2024 by Dow Jones
8:46AM ET on Monday Jun 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Actinium Pharmaceuticals Inc | 219.5M | -4.3x | --- |
Greenwich Lifesciences Inc | 220.2M | -23.8x | --- |
Omeros Corp | 221.3M | -1.3x | --- |
ESSA Pharma Inc | 221.4M | -7.9x | --- |
ATAI Life Sciences NV | 217.6M | -5.4x | --- |
Solid Biosciences Inc | 222.6M | -1.4x | --- |
Company Information
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Contact Information
- Headquarters
- 100 Park Ave., 23Rd FloorNEW YORK, NY, United States 10017
- Phone
- 646-677-3870
- Fax
- 845-818-3588
Executives
- Chairman of the Board, Chief Executive Officer
- Sandesh Seth
- Chief Financial Officer
- Steve O'Loughlin
- Chief Business Officer
- Lynn Bodarky
- Independent Director
- Jeffrey Chell
- Lead Independent Director
- C. David Nicholson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $219.5M |
|---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.20 |
EPS | $-1.72 |
Book Value | $1.32 |
P/E Ratio | -4.3x |
Price/Sales (TTM) | 2,709.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61,645.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
